These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26813548)

  • 21. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease.
    Sorbets E; Greenlaw N; Ferrari R; Ford I; Fox KM; Tardif JC; Tendera M; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):797-806. PubMed ID: 28561986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Parodi G; Bellandi B; Valenti R; Memisha G; Giuliani G; Velluzzi S; Migliorini A; Carrabba N; Antoniucci D
    Atherosclerosis; 2010 Jul; 211(1):255-9. PubMed ID: 20226462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial.
    Jensen MT; Kaiser C; Sandsten KE; Alber H; Wanitschek M; Iversen A; Jensen JS; Pedersen S; Soerensen R; Rickli H; Zurek M; Fahrni G; Bertel O; De Servi S; Erne P; Pfisterer M; Galatius S;
    Int J Cardiol; 2013 Oct; 168(4):3802-6. PubMed ID: 23849965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical characteristics and prognosis comparison of Chinese non ST-segment elevation acute coronary syndrome patients in two different time periods].
    Bai Y; Liang Y; Tan H; Qiao S; Zhang J; Yang Y; Zhang Y; Zhu J; ;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Aug; 42(8):655-60. PubMed ID: 25388338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resting heart rate and real-life treatment modalities in outpatients with left ventricular systolic dysfunction study: A multicenter, prospective, observational, and national registry.
    Çavuşoğlu Y; Kozan Ö; Temizhan A; Küçükoğlu MS
    Anatol J Cardiol; 2021 May; 25(5):304-312. PubMed ID: 33960305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension is associated with increased mortality in patients with ischaemic heart disease after revascularization with percutaneous coronary intervention - a report from SCAAR.
    Saluveer O; Redfors B; Angerås O; Dworeck C; Haraldsson I; Ljungman C; Petursson P; Odenstedt J; Ioanes D; Lundgren P; Völz S; Råmunddal T; Andersson B; Omerovic E; Bergh N
    Blood Press; 2017 Jun; 26(3):166-173. PubMed ID: 28092977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen.
    Guaricci AI; Maffei E; Brunetti ND; Montrone D; Di Biase L; Tedeschi C; Gentile G; Macarini L; Midiri M; Cademartiri F; Di Biase M
    Int J Cardiol; 2013 Sep; 168(1):362-8. PubMed ID: 23063141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart Rate as a Predictor of Outcome Following Percutaneous Coronary Intervention.
    O'Brien J; Reid CM; Andrianopoulos N; Ajani AE; Clark DJ; Krum H; Loane P; Freeman M; Sebastian M; Brennan AL; Shaw J; Dart AM; Duffy SJ;
    Am J Cardiol; 2018 Oct; 122(7):1113-1120. PubMed ID: 30107905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
    Tardif JC; Ponikowski P; Kahan T;
    Int J Cardiol; 2013 Sep; 168(2):789-94. PubMed ID: 23138014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of resting heart rate with antianginal drugs: review and meta-analysis.
    Cucherat M; Borer JS
    Am J Ther; 2012 Jul; 19(4):269-80. PubMed ID: 21804377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry.
    Danchin N; Ferrieres J; Guenoun M; Cattan S; Rushton-Smith SK; Greenlaw N; Ferrari R; Steg PG;
    Arch Cardiovasc Dis; 2014; 107(8-9):452-61. PubMed ID: 25128934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
    Bangalore S; Steg G; Deedwania P; Crowley K; Eagle KA; Goto S; Ohman EM; Cannon CP; Smith SC; Zeymer U; Hoffman EB; Messerli FH; Bhatt DL;
    JAMA; 2012 Oct; 308(13):1340-9. PubMed ID: 23032550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of ivabradin to reduce heart rate prior to coronary CT angiography: comparison with beta-blocker.
    Bayraktutan U; Kantarci M; Gundogdu F; Demirelli S; Yuce I; Oğul H; Duran C; Taş H; Şimşek Z; Karabulut N
    Diagn Interv Radiol; 2012; 18(6):537-41. PubMed ID: 22729428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a Failure to Optimize theRapy in anGina pEcToris (FORGET) study?
    Elder DH; Pauriah M; Lang CC; Shand J; Menown IB; Sin BD; Gupta S; Duckett SG; Foster W; Zachariah D; Kalra PR
    QJM; 2010 May; 103(5):305-10. PubMed ID: 20181676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study).
    Fu M; Ahrenmark U; Berglund S; Lindholm CJ; Lehto A; Broberg AM; Tasevska-Dinevska G; Wikstrom G; Ågard A; Andersson B;
    Clin Res Cardiol; 2017 Dec; 106(12):960-973. PubMed ID: 28795299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
    Ozasa N; Morimoto T; Bao B; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Tazaki J; Natsuaki M; Kimura T;
    Int J Cardiol; 2013 Sep; 168(2):774-9. PubMed ID: 23127614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.
    Rimoldi SF; Messerli FH; Cerny D; Gloekler S; Traupe T; Laurent S; Seiler C
    Hypertension; 2016 Jun; 67(6):1205-10. PubMed ID: 27091900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of left ventricular ejection fraction and heart rate values in a cohort of stable coronary patients: the INDYCE registry.
    Tabet JY; Malergue MC; Guenoun M; Paganelli F; Meurin P; Not D; Jourdain P; Guedj-Meynier D;
    Arch Cardiovasc Dis; 2010; 103(6-7):354-62. PubMed ID: 20800799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.